Glenview Trust Co Invests $553,000 in CVS Health Corporation $CVS

Glenview Trust Co acquired a new position in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 7,703 shares of the pharmacy operator’s stock, valued at approximately $553,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of CVS Health in the second quarter valued at approximately $12,747,462,000. State Street Corp increased its holdings in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after purchasing an additional 1,245,457 shares in the last quarter. Capital International Investors lifted its position in shares of CVS Health by 3.4% during the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of CVS Health by 148.0% in the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after acquiring an additional 13,836,701 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of CVS Health in the 4th quarter valued at about $1,666,265,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 0.2%

CVS Health stock opened at $93.15 on Friday. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $119.14 billion, a PE ratio of 24.64, a PEG ratio of 0.91 and a beta of 0.61. The business’s 50-day simple moving average is $101.42 and its 200-day simple moving average is $89.46.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the firm posted $1.81 EPS. The company’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS’ Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CVS. Cantor Fitzgerald raised their price target on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Robert W. Baird set a $107.00 price target on CVS Health in a research note on Thursday, August 6th. Piper Sandler reissued an “overweight” rating on shares of CVS Health in a research note on Wednesday. Weiss Ratings upgraded CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Finally, Morgan Stanley increased their target price on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $107.17.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.